US approves Janssen’s HIV pill Symtuza
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
Read More
Tag: tenofovir
National PreP service would be cost effective, research finds
Providing pre-exposure prophylaxis (PrEP) treatment to men who have sex with men at high risk of contracting HIV in England would be cost-effective and could prevent 25 percent of cases of infection, according to UCL research.
Read More
Janssen’s HIV combo pill hits safety, efficacy targets
Janssen Pharmaceutica’s experimental combination therapy for HIV containing four medicines in a single pill has hit safety and efficacy targets in a late stage trial, results of which have been published in The Lancet HIV.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
